[go: up one dir, main page]

NO20063951L - Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom - Google Patents

Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom

Info

Publication number
NO20063951L
NO20063951L NO20063951A NO20063951A NO20063951L NO 20063951 L NO20063951 L NO 20063951L NO 20063951 A NO20063951 A NO 20063951A NO 20063951 A NO20063951 A NO 20063951A NO 20063951 L NO20063951 L NO 20063951L
Authority
NO
Norway
Prior art keywords
methods
preparations
metastatic disease
immunoglobulins
treating tumors
Prior art date
Application number
NO20063951A
Other languages
English (en)
Inventor
Nancy Wehner
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of NO20063951L publication Critical patent/NO20063951L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparater, fremgangsmåter og kombinasjonsterapier til behandlingen av lymfomer, leukemier, melanomer, prostatakreft og metastatisk sykdom blir tilveiebrakt. Spesifikt blir preparater som omfatter anti-a-integrinimmunoglobuliner eller immunoglobuliner som binder til en aintegrinligand (f.eks. MadCAM-1 og VCAM-1) tilkjennegj ort til anvendelse for å inhibere tumorvekst og progresjon og inhibering av metastaser. Et foretrukket immunoglobulin til anvendelse for å behandle tumorer og metastaser er natalizumab. Preparatene og fremgangsmåtene som benytter disse immunoglobulinene kan bli benyttet alene eller i kombinasjon med andre reagenser og kreftbehandlingsmodaliteter.
NO20063951A 2004-02-06 2006-09-05 Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom NO20063951L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54194604P 2004-02-06 2004-02-06
PCT/US2005/002860 WO2005076843A2 (en) 2004-02-06 2005-02-03 Methods and compositions for treating tumors and metastatic disease

Publications (1)

Publication Number Publication Date
NO20063951L true NO20063951L (no) 2006-11-02

Family

ID=34860234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063951A NO20063951L (no) 2004-02-06 2006-09-05 Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom

Country Status (19)

Country Link
US (1) US20050255118A1 (no)
EP (2) EP1718310A4 (no)
JP (1) JP4996261B2 (no)
KR (1) KR20070009581A (no)
CN (1) CN1946407B (no)
AR (1) AR047534A1 (no)
AU (1) AU2005213324B2 (no)
BR (1) BRPI0507451A (no)
CA (1) CA2555365A1 (no)
EA (1) EA009873B1 (no)
IL (1) IL177201A0 (no)
MX (1) MXPA06008746A (no)
NO (1) NO20063951L (no)
NZ (1) NZ584288A (no)
PE (1) PE20060009A1 (no)
TW (1) TWI375563B (no)
UY (1) UY28741A1 (no)
WO (1) WO2005076843A2 (no)
ZA (1) ZA200606557B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200506159B (en) 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
CN1956738B (zh) 2004-01-09 2013-05-29 辉瑞大药厂 MAdCAM抗体
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
CA2675291C (en) * 2007-01-11 2017-05-23 Novo Nordisk A/S Killer ig-like receptor (kir) antibodies, formulations, and uses thereof
CA2708262A1 (en) * 2007-12-07 2009-06-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
US20110110940A1 (en) * 2008-04-15 2011-05-12 Oxigene, Inc. Methods for Enhancing the Efficacy of Vascular Disrupting Agents
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
SG175166A1 (en) * 2009-04-17 2011-11-28 Biogen Idec Inc Compositions and methods to treat acute myelogenous leukemia
US20110158982A1 (en) * 2009-10-05 2011-06-30 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
JP5847188B2 (ja) 2010-10-25 2016-01-20 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法
WO2013013302A1 (en) * 2011-07-22 2013-01-31 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
CA2863679A1 (en) 2011-08-17 2014-05-30 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
WO2014018913A2 (en) * 2012-07-27 2014-01-30 University Of Connecticut Santacruzamate a compositions and analogs and methods of use
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
RU2527154C1 (ru) * 2013-03-27 2014-08-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ повышения биодоступности цисплатина в саркому -45, индуцированную в эксперименте
ES2728305T3 (es) * 2013-04-29 2019-10-23 Ogd2 Pharma Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
JP6855243B2 (ja) 2014-01-24 2021-04-07 エイアイ・セラピューティクス・インコーポレーテッド 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
KR20170098812A (ko) 2014-11-07 2017-08-30 램 테라퓨틱스, 인코포레이티드 신장암의 치료에 사용하기 위한 아필리모드
US20190209576A1 (en) 2014-11-07 2019-07-11 AI Therapeutics, Inc. Apilimod for use in the treatment of colorectal cancer
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017011907A1 (en) 2015-07-17 2017-01-26 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
RU2650587C1 (ru) * 2017-04-26 2018-04-16 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ модификации хронической болью злокачественного роста меланомы в16 у мышей
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam
JP7520818B2 (ja) * 2018-09-13 2024-07-23 ンカルタ・インコーポレイテッド 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
RU2765955C1 (ru) * 2021-03-30 2022-02-07 Елена Рудольфовна Милаева Средство для ингибирования метастазирования в легких
RU2762730C1 (ru) * 2021-03-30 2021-12-22 Елена Рудольфовна Милаева Средство для ингибирования метастазирования в легких
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
DK0678122T3 (da) * 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
WO1998037902A1 (en) * 1997-02-28 1998-09-03 The Regents Of The University Of California Inhibition of cell-cell binding by lipid assemblies
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DK1113810T3 (da) * 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
DE60043308D1 (de) 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
WO2002045653A2 (en) * 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
EP1401484A1 (en) * 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
WO2003019136A2 (en) * 2001-08-06 2003-03-06 The Regents Of The University Of California Methods for inhibiting angiogenesis
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
EP1682179A4 (en) * 2003-11-05 2008-09-03 Palingen Inc IMPROVED B-CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor

Also Published As

Publication number Publication date
EA009873B1 (ru) 2008-04-28
NZ584288A (en) 2011-10-28
WO2005076843A3 (en) 2006-01-26
ZA200606557B (en) 2008-02-27
JP2007520557A (ja) 2007-07-26
AU2005213324B2 (en) 2011-06-09
CN1946407B (zh) 2011-10-05
PE20060009A1 (es) 2006-02-11
MXPA06008746A (es) 2007-01-23
EP2394652A3 (en) 2012-10-24
BRPI0507451A (pt) 2007-07-10
UY28741A1 (es) 2005-08-31
TW200536556A (en) 2005-11-16
EP1718310A4 (en) 2009-05-06
KR20070009581A (ko) 2007-01-18
AR047534A1 (es) 2006-01-25
AU2005213324A1 (en) 2005-08-25
CA2555365A1 (en) 2005-08-25
EP1718310A2 (en) 2006-11-08
US20050255118A1 (en) 2005-11-17
EA200601433A1 (ru) 2007-02-27
JP4996261B2 (ja) 2012-08-08
IL177201A0 (en) 2006-12-10
CN1946407A (zh) 2007-04-11
WO2005076843A2 (en) 2005-08-25
TWI375563B (en) 2012-11-01
EP2394652A2 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
NO20063951L (no) Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom
MX2023005375A (es) Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
MX373790B (es) Anticuerpos humanos a ligando de muerte programada 1 (pd-l1).
DE602005016773D1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
ATE546158T1 (de) Therapeutisches krebsmittel mit polymergebundenem antikörper
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
EA201992575A1 (ru) Биомаркеры для терапии рака
EA201391423A1 (ru) Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты
ATE531388T1 (de) Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
Robert et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients
Yajima et al. Anti-androgen therapy for the patients with recurrent and/or metastatic salivary duct carcinoma expressing androgen receptors: a retrospective study
DE60030696D1 (de) Spezifische antikörper für cyp1b1
O'Reilly et al. A phase 2, open-label, multicenter study of durvalumab (MEDI4736)±tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.
Alsina et al. Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer.
Schadendorf et al. Combi-D: Quality of Life (Qol) Impact of the Combination of Dabrafenib and Trametinib (D+ T) Versus Dabrafenib Monotherapy (D) in Patients with Braf V600E/K Unresectable or Metastatic Melanoma in a Phase III Trial
Wang et al. A combined local treatment with anti-PD-1 antibody and bone marrow derived dendritic cells after x-ray irradiation to subcutaneous melanoma in a murine model.
DE60331834D1 (de) VERWENDUNG EINES ANTIKÖRPERS ANTI-PTHrP(34-53) ALS ANTAGONIST VON PTHrP ZUR BEHANDLUNG VON NIERENZELLKARZINOMA
Hellmann 2.1 Preclinical Data–In Vitro and In Vivo
Królicki et al. Secondary glioblastoma multiforme–local alpha emitters targeted therapy with 213Bi-DOTA-substance P
Ferhatoğlu Clinicopathologic and prognostic features in appendiceal malignancies: Does tumor invasiveness matter?
Yakovleva Treatment for oral mucosal cancer
Rusakov et al. CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER
Kang Surgical Standardization in Extent of Lymph Node Dissection for Treating Intrahepatic Cholangiocelluar Carcinoma: Complete LN Dissection vs. LN Sampling: Complete LN Dissection vs. LN Sampling
Kostyu et al. DIFFERENTIATED SURGICAL TACTICS IN PATIENTS WITH LOCALLY ADVANCED BLADDER INVOLVEMENT PELVIC TUMORS
Moiseenko et al. ANATOMICAL LANDMARKS FOR ROBOTIC NERVE SPARING RADICAL PROSTATECTOMY

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application